email print share on Facebook share on Twitter share on LinkedIn share on reddit pin on Pinterest

DISTRIBUTION UK

Cannes buying spree continues

by 

The fevered acquisition of hot Cannes titles continues with Artificial Eye and Momentum announcing further purchases for the UK market.

Artificial Eye has added two more to its already bulging Cannes kitty with the addition of Barbet Schroeder’s Terror’s Advocate [+see also:
trailer
film profile
]
and Roy Andersson’s You, the Living [+see also:
film review
trailer
interview: Pernilla Sandström
interview: Roy Andersson
film profile
]
. Both films premiered in the Un Certain Regard section of the festival.

(The article continues below - Commercial information)
Hot docs EFP inside

“Artificial Eye brings the best of world cinema to its audiences and with our recent acquisition of Terror's Advocate, You, The Living and The Island we have a total of 11 new titles purchased at Cannes, including the Palme d'Or (and Fipresci Prize) Winner, 4 Months, 3 Weeks & 2 Days [+see also:
film review
trailer
interview: Cristian Mungiu
interview: Oleg Mutu
film profile
]
; The Banishment, which won the Best Actor prize for Konstantin Lavronenko; and The Edge of Heaven [+see also:
film review
trailer
interview: Fatih Akin
interview: Klaus Maeck
film profile
]
, which won Best Screenplay and the Ecumenical Award,” said Robert Beeson, managing director of Artificial Eye.

Momentum in the meanwhile snapped up UK distribution rights to Nadine Labaki’s Caramel [+see also:
trailer
film profile
]
, which premiered in the Directors’ Fortnight at Cannes. Labaki’s winning debut, which she also wrote and starred in, is a romantic comedy where five women gather in a Beirut beauty salon and discuss a range of matters varying from affairs of the heart to religion. Richard Napper, managing director of Momentum, hailed Labaki as “a fresh new voice in world cinema.”

Artificial Eye has also picked up UK rights for The Island, the closing film of the 2006 Venice Film Festival.

(The article continues below - Commercial information)

Did you enjoy reading this article? Please subscribe to our newsletter to receive more stories like this directly in your inbox.

Privacy Policy